Clay B. Siegall - 02 Oct 2023 Form 3 Insider Report for Immunome Inc. (IMNM)

Role
President and CEO, Director
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Issuer symbol
IMNM
Transactions as of
02 Oct 2023
Net transactions value
$0
Form type
3
Filing time
04 Oct 2023, 17:34:03 UTC
Previous filing
13 May 2022
Next filing
15 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMNM Common Stock 150,432 02 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMNM Stock Option (Right to Buy) 02 Oct 2023 Common Stock 198,565 $1.35 Direct F1, F2
holding IMNM Stock Option (Right to Buy) 02 Oct 2023 Common Stock 1,191,399 $1.35 Direct F1, F2
holding IMNM Stock Option (Right to Buy) 02 Oct 2023 Common Stock 2,137,080 $5.91 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Siegall was elected as a member of the board of directors and appointed as President and Chief Executive Officer of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization, dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Dr. Siegall joining the board of directors and being appointed an executive officer of the Issuer, Dr. Siegall exchanged his (i) options to acquire shares of common stock of Morphimmune Inc. for options to acquire shares of the Issuer and (ii) his shares of capital stock of Morphimmune for shares of common stock of the Issuer.
F2 In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.
F3 25% of the shares vest and become exercisable at the one-year anniversary of the consummation of the merger contemplated by the Merger Agreement; and 75% of the shares vest and become exercisable in thirty-six (36) successive equal monthly installments thereafter.

Remarks:

See Attached Exhibit 24